IRIDEX Corp (IRIX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.70-0.10%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · IRIX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue efforts to generate positive operating cash flow and adjusted EBITDA, reversing prior losses and preserving cash.
Stated as a priority in 4 quarters including 2025-Q2, 2025-Q4, 2026-Q1, and 2026-Q2. The Company achieved operating cash flow positive in 2026-Q2 and expects positive cash flow for full year 2026. Net loss improved from -$0.5M in 2026-Q1 to -$1.3M in 2026-Q2, with adjusted EBITDA fluctuating but showing narrowing losses. The trajectory shows delivering progress toward cash flow positive operations.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“CEO: 'Operating cash flow positive second quarter 2026.'”
“CEO: 'We remain confident in our ability to deliver on... cash flow positive fiscal year.'”
“The Company plans to achieve cash flow breakeven in the fourth quarter and positive adjusted EBITDA in 2025.”
“The Company plans to achieve cash flow breakeven and positive adjusted EBITDA in 2025 on revenue generation consistent with 2024.”
Maintain revenue guidance for full year 2026 between $51 million and $53 million despite market disruptions.
Reaffirmed in 4 consecutive quarters from 2025-Q3 through 2026-Q2. Revenue guidance remains steady at $51 million to $53 million for full year 2026. Actual quarterly revenues showed slight declines but management maintains guidance, indicating a stable but challenged revenue outlook.
“The Company is reaffirming its annual revenue guidance for the full year 2026 of between $51 million and $53 million.”
“The Company is reaffirming its annual revenue guidance for the full year 2026 of between $51 million and $53 million.”
“The Company currently forecasts 2026 revenue of between $51 million and $53 million.”
“The Company currently forecasts 2026 revenue of between $51 million and $53 million.”
Maintain adjusted operating expenses in the range of $19 million to $19.5 million for fiscal year 2026.
Stated in 4 quarters from 2025-Q3 through 2026-Q2. Management expects adjusted operating expenses between $19 million and $19.5 million for 2026. Operating expenses decreased slightly from $5.6 million in 2025-Q2 to $5.3 million in 2026-Q2, showing limited progress but consistent cost control efforts.
“The Company continues to expect fiscal year 2026 adjusted operating expenses... to be in the range of $19 million to $19.5 million.”
“For 2026 adjusted operating expenses... are expected to be in the range of $19 million to $19.5 million.”
“For 2026 adjusted operating expenses... are expected to be in the range of $19 million to $19.5 million.”
“For 2026 adjusted operating expenses... are expected to be in the range of $19 million to $19.5 million.”
Grow sales and utilization of the Cyclo G6 product family, including probes and laser systems.
Stated in 2 quarters, 2026-Q1 and 2026-Q2. Cyclo G6 product family revenue grew 14% in 2026-Q1 and 19% in 2026-Q2 year-over-year, driven by increased probe sales. This shows delivering growth in this product line consistent with management's stated priority.
“Cyclo G6 product family revenue was $3.9 million, growth of 19% year-over-year.”
“Cyclo G6 product family revenue was $3.6 million, growth of 14% year-over-year.”
Transfer production to lower cost contract manufacturers and relocate headquarters to reduce costs and improve profitability.
Stated in 2 quarters, 2026-Q1 and 2026-Q2. Management reports ongoing progress in transferring production to lower cost contract manufacturers and relocating headquarters to reduce costs. Operating expenses decreased modestly, indicating limited but consistent progress on this cost reduction priority.
“CEO: 'Continuing to make significant progress transforming our business, including transfer of production to lower cost contract manufacturers and relocation of headquarters.'”
“CEO: 'Cost structure improvements are flowing through as planned.'”
Over the trailing year it converted 0.59x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.